Merck Gross Margin 2010-2024 | MRK

Current and historical gross margin for Merck (MRK) over the last 10 years. The current gross profit margin for Merck as of March 31, 2024 is %.
Merck Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $61.40B $45.66B 74.37%
2023-12-31 $60.12B $43.99B 73.17%
2023-09-30 $59.31B $43.22B 72.86%
2023-06-30 $58.31B $42.55B 72.96%
2023-03-31 $57.87B $41.91B 72.43%
2022-12-31 $59.28B $41.87B 70.63%
2022-09-30 $58.97B $41.57B 70.49%
2022-06-30 $57.17B $40.25B 70.41%
2022-03-31 $53.98B $38.17B 70.72%
2021-12-31 $48.70B $35.08B 72.02%
2021-09-30 $44.36B $30.06B 67.77%
2021-06-30 $42.14B $28.28B 67.10%
2021-03-31 $40.09B $26.58B 66.31%
2020-12-31 $41.52B $27.90B 67.20%
2020-09-30 $36.49B $25.84B 70.83%
2020-06-30 $37.96B $26.33B 69.38%
2020-03-31 $40.36B $28.09B 69.59%
2019-12-31 $39.12B $27.11B 69.29%
2019-09-30 $45.97B $32.24B 70.13%
2019-06-30 $44.37B $31.01B 69.89%
2019-03-31 $43.07B $29.70B 68.94%
2018-12-31 $42.29B $28.79B 68.06%
2018-09-30 $41.73B $28.07B 67.26%
2018-06-30 $41.26B $27.91B 67.65%
2018-03-31 $40.73B $27.68B 67.96%
2017-12-31 $40.12B $27.21B 67.82%
2017-09-30 $39.80B $26.86B 67.48%
2017-06-30 $40.02B $26.97B 67.40%
2017-03-31 $39.93B $26.42B 66.17%
2016-12-31 $39.81B $25.78B 64.75%
2016-09-30 $39.91B $25.50B 63.89%
2016-06-30 $39.44B $24.68B 62.58%
2016-03-31 $39.39B $24.45B 62.07%
2015-12-31 $39.50B $24.56B 62.19%
2015-09-30 $39.77B $24.93B 62.70%
2015-06-30 $40.25B $24.95B 62.00%
2015-03-31 $41.40B $24.96B 60.30%
2014-12-31 $42.24B $25.47B 60.30%
2014-09-30 $43.08B $25.45B 59.08%
2014-06-30 $43.55B $26.04B 59.80%
2014-03-31 $43.63B $26.73B 61.27%
2013-12-31 $44.03B $27.08B 61.50%
2013-09-30 $44.45B $27.94B 62.86%
2013-06-30 $44.91B $28.37B 63.17%
2013-03-31 $46.21B $29.84B 64.58%
2012-12-31 $47.27B $30.82B 65.21%
2012-09-30 $47.82B $31.36B 65.58%
2012-06-30 $48.36B $31.68B 65.51%
2012-03-31 $48.20B $31.35B 65.04%
2011-12-31 $48.05B $31.18B 64.89%
2011-09-30 $47.85B $30.71B 64.19%
2011-06-30 $46.95B $29.98B 63.85%
2011-03-31 $46.15B $28.91B 62.64%
2010-12-31 $45.99B $27.59B 60.00%
2010-09-30 $43.99B $25.13B 57.13%
2010-06-30 $38.91B $22.81B 58.63%
2010-03-31 $33.47B $20.56B 61.45%
2009-12-31 $27.43B $18.41B 67.11%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $324.174B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11